Topic: Pay for delay

Zetia claims win magistrate blessing

Glenmark Pharmaceuticals and Merck should have to face pay-for-delay claims over the cholesterol-lowering drug Zetia at trial, a federal magistrate judge has said.

07 September 2022

Oral hearings not essential for fair appeals, CAT president says

The UK’s Competition Appeal Tribunal can oversee a fair appeal process without holding a hearing, its president has said while rejecting drugmakers' claims that oral submissions are a fundamental part of their appeals against excessive pricing penalties.

25 July 2022

All Servier agreements were by-object restrictions, AG Kokott says

The European Court of Justice should set aside a General Court decision that found agreements between Servier and generics drugmaker Krka did not constitute by-object or by-effect restrictions of competition, EU advocate general Juliane Kokott has said.

14 July 2022

Delaware court dismisses Accord claims in Seroquel antitrust litigation

Plaintiffs have failed to allege that AstraZeneca’s purported pay-for-delay agreement with Accord Healthcare harmed competition in the market for psychiatric medication Seroquel XR, a federal court has ruled.

07 July 2022

Second Circuit: Southern District of New York

Featured in US Courts Annual Review - Edition 3

24 June 2022

CMA fines pharma companies for restricting drug supplies

The UK’s antitrust watchdog has fined four pharmaceutical companies and a private equity group more than £35 million for agreeing to limit the supply of an anti-nausea tablet to the National Health Service, causing prices to rise by 700%.

03 February 2022

FTC closes sham lawsuit case against AbbVie

The Federal Trade Commission has withdrawn its case against AbbVie after a Supreme Court ruling in April determined that the agency does not have the authority to seek restitution or disgorgement under Section 13(b) of the FTC Act.

02 August 2021

Mylan secures victory in another EpiPen case

A federal Kansas judge has dismissed a pharmacy operator’s putative class action accusing Mylan and Pfizer of illegally monopolising the market for epinephrine auto-injectors used to treat severe allergic reactions.

28 July 2021

Takeda and Endo hit with pay-for-delay claims

Takeda Pharmaceutical and Endo International are facing a lawsuit over an alleged scheme to block generic competition to Takeda’s branded anti-constipation drug Amitiza.

28 June 2021

Health authorities should have pushed alternative medication, Servier tells UK court

Servier has kicked off its bid to convince a UK court that national health authorities should have encouraged doctors to prescribe cheaper generic drugs to mitigate their losses from its pay-for-delay settlements relating to a blood pressure medication.

17 June 2021

Unlock unlimited access to all Global Competition Review content